Tracking biopharma's response to the new coronavirus

The ongoing outbreak is a huge test for the biopharmaceutical industry and its ability to supply, develop, and test new drugs without disruption. Keep up with all of BioPharma Dive's coverage here.

By Jacob Bell • Updated July 7, 2020

Federal prosecutors make another claim against Mallinckrodt over Acthar prices

A quirk in the FDA approval for the multi-use drug allowed first Questcor and then Mallinckrodt to understate rebates owed to Medicaid, the lawsuit claims.

By Jonathan Gardner • March 4, 2020

Explore the Trendline➔

Emerging biotech

New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.

By BioPharma Dive staff

In a CRISPR first, Editas therapy used to fix genes in the body

A patient with a severe type of inherited blindness was recently treated with Editas and Allergan's CRISPR medicine, marking the first in vivo use of the gene-editing technology in adults. 

By Ned Pagliarulo • March 4, 2020

New estimate puts cost to develop a new drug at $1B, adding to long-running debate

Pharma companies spend $300 million to $400 million bringing a new medicine to market, but per-product R&D costs are much higher after accounting for the many drugs that fail in testing.

By Jonathan Gardner • March 3, 2020

Gilead breaks M&A lull with $5B immuno-oncology deal

The bid for Forty Seven, a California biotech with a mid-stage cancer agent, comes at a high double-digit premium. Analysts expect it's the first of several near-term buyouts for Gilead.

By Jacob Bell • March 2, 2020

Cell therapy developer Unum restructures, cutting staff in pivot

A preclinical cell therapy will be Unum's focus moving forward, while two early-stage studies will be discontinued.

By Ned Pagliarulo • March 2, 2020

Karyopharm shares jump on positive study data for multiple myeloma drug

The cancer biotech now plans to ask the FDA to expand Xpovio's approval into earlier lines of treatment for the blood cancer.

By Ned Pagliarulo • March 2, 2020

Sangamo sees vindication in Biogen gene-editing deal

Delivering products nearly ready for clinical testing has sparked greater dealmaking interest from big pharma, Sangamo's CEO told BioPharma Dive.

By Jonathan Gardner • Feb. 28, 2020

Biogen, Sangamo look to tackle Alzheimer's, Parkinson's through gene regulation

A new collaboration between the biotechs hands Sangamo $350 million upfront and potentially billions more in milestones in exchange for a license to a dozen neurological disease targets.

By Jacob Bell • Feb. 27, 2020

FDA pushes back decision on Zogenix epilepsy drug

Shares sank on concerns about the future of the drug designed to treat Dravet syndrome, a rare form of epilepsy.

By Kristin Jensen • Feb. 27, 2020

Gilead commits to in-house development of coronavirus treatment hopeful

The biotech launched two global, Phase 3 studies of remdesivir, an experimental antiviral already being studied in trials run by Chinese researchers and the NIH.

By Ned Pagliarulo • Feb. 27, 2020

Takeda's small celiac disease bet turns into acquisition

Phase 1 data triggered a takeout of PvP Biologics worth up to $330 million, giving Takeda access to a drug invented by a University of Washington team.

By Jonathan Gardner • Feb. 26, 2020

BioMarin inches closer to a gene therapy first

A decision by the FDA on whether to approve valrox, potentially the first gene therapy for hemophilia, should come by late August. 

By Jacob Bell • Feb. 21, 2020

GSK taps Immatics' cell therapy science in research deal

For $50 million upfront, the British pharma will gain access to two T cell therapies Immatics is developing to treat solid tumors. 

By Ned Pagliarulo • Feb. 20, 2020

Tocagen restructuring leads to reverse merger with Forte

After a Phase 3 brain cancer study missed its goal last fall, Tocagen laid off two-thirds of its workforce and began evaluating its options.

By Ned Pagliarulo • Feb. 20, 2020

Bluebird's gene therapy hits another delay, this time in the US

The disclosure of a longer timeline until the biotech fully submits LentiGlobin for U.S. approval sent shares sliding and spurred one analyst to downgrade the stock.

By Jacob Bell • Feb. 19, 2020

The cancer genes Wall Street is flooding with cash

Revolution Medicines, a biotech working on cancer drugs that target what are known as RAS genes, announced Wednesday it's raising $238 million through a public offering — more than double its initial goal.

By Jacob Bell • Feb. 13, 2020

Exelixis prostate cancer data could help stave off competitive threats

As Pfizer makes inroads against Cabometyx in kidney cancer, Exelixis said it will ask the FDA next year for approval in prostate disease.

By Jonathan Gardner • Feb. 11, 2020

Moderna, raising cash, quickly advances coronavirus candidate

A initial batch of the biotech's mRNA vaccine could soon be sent to the NIH for use in a Phase 1 study, which would mark a rapid scale-up to clinical testing. 

By Ned Pagliarulo • Feb. 11, 2020

Biogen dips as Alzheimer's drugs from Lilly, Roche fail again

Analysts have said that, should the DIAN-TU study miss, it may further paint Biogen's aducanumab and the positive Phase 3 data it generated as an "artifact of luck" within a series of failed amyloid-targeting drugs.

By Jacob Bell • Feb. 10, 2020

Biohaven misses a chance to prove it's more than migraine

One of Biohaven's late-stage drugs proved no better than placebo in a type of severe anxiety — a lost opportunity for the company to showcase a pipeline beyond its lead migraine therapy.

By Ned Pagliarulo • Feb. 10, 2020

Kite isn't flying with investors, and Gilead knows it

On Tuesday, Gilead acknowledged the cell therapy developer is worth less than it once thought, cutting the accounting value for research assets it acquired by $800 million. 

By Ned Pagliarulo • Feb. 5, 2020

Nestlé boosts investment as Aimmune preps launch of peanut allergy drug

With $200 million more in the bank, the biotech also in-licensed an experimental next-generation food allergy therapy from Xencor. 

By Jonathan Gardner • Updated Feb. 5, 2020

Regeneron partners with US government to develop coronavirus treatment

The biotech hopes to replicate its past success in quickly advancing a treatment for Ebola. But, as that experience showed, proving a new antiviral isn't easy.

By Ned Pagliarulo • Updated Feb. 4, 2020

January price increases confirm slowing drug inflation

Pfizer, GlaxoSmithKline and Allergan were the most active, collectively raising list prices on some 450 drugs, according to one Wall Street analyst.

By Jonathan Gardner • Feb. 4, 2020